CRBP vs. LUMO, NLTX, STSA, CPIX, KALA, IMPL, LPCN, RNXT, TFFP, and MBRX
Should you be buying Corbus Pharmaceuticals stock or one of its competitors? The main competitors of Corbus Pharmaceuticals include Lumos Pharma (LUMO), Neoleukin Therapeutics (NLTX), Satsuma Pharmaceuticals (STSA), Cumberland Pharmaceuticals (CPIX), Kala Pharmaceuticals (KALA), Impel Pharmaceuticals (IMPL), Lipocine (LPCN), RenovoRx (RNXT), TFF Pharmaceuticals (TFFP), and Moleculin Biotech (MBRX). These companies are all part of the "pharmaceutical preparations" industry.
Corbus Pharmaceuticals vs.
Corbus Pharmaceuticals (NASDAQ:CRBP) and Lumos Pharma (NASDAQ:LUMO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, community ranking, valuation, media sentiment, earnings and analyst recommendations.
Corbus Pharmaceuticals received 399 more outperform votes than Lumos Pharma when rated by MarketBeat users. However, 71.43% of users gave Lumos Pharma an outperform vote while only 68.72% of users gave Corbus Pharmaceuticals an outperform vote.
In the previous week, Lumos Pharma had 1 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 1 mentions for Lumos Pharma and 0 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 0.98 beat Lumos Pharma's score of 0.76 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media.
Lumos Pharma has higher revenue and earnings than Corbus Pharmaceuticals. Lumos Pharma is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Corbus Pharmaceuticals currently has a consensus target price of $3.00, suggesting a potential downside of 54.95%. Lumos Pharma has a consensus target price of $17.67, suggesting a potential upside of 428.94%. Given Lumos Pharma's higher possible upside, analysts clearly believe Lumos Pharma is more favorable than Corbus Pharmaceuticals.
Corbus Pharmaceuticals has a net margin of 0.00% compared to Lumos Pharma's net margin of -2,039.53%. Lumos Pharma's return on equity of -43.80% beat Corbus Pharmaceuticals' return on equity.
18.7% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 30.5% of Lumos Pharma shares are held by institutional investors. 6.3% of Corbus Pharmaceuticals shares are held by insiders. Comparatively, 21.2% of Lumos Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Corbus Pharmaceuticals has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500. Comparatively, Lumos Pharma has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500.
Summary
Lumos Pharma beats Corbus Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Corbus Pharmaceuticals Competitors List